Medical Devices · Published Aug 2026
Single-Use Assemblies Market
The single-use assemblies market is projected to expand from USD 15,930.0 million in 2025 to USD 29,071.1 million by 2035, reflecting a steady 6.2% CAGR over the decade. This trajectory is underpinned by rising demand in biopharmaceutical manufacturing, where single-use technologies reduce cross-contamination risks and streamline production cycles. In Q1 2025, Medtronic announced the commercial launch of its next-generation single-use bioreactor system, designed to support scalable cell culture processes for gene therapies.
Abbott’s acquisition of a filtration technology firm in March 2025 further validated the sector’s consolidation trend, emphasizing the shift toward integrated, closed-system solutions. The market’s growth is also fueled by regulatory pressures in pharmaceutical manufacturing, which increasingly favor disposable assemblies to enhance compliance with GMP standards.
Market size
Growth trajectory through 2035
Single-Use Assemblies Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Medtronic launched the Xcellerex XDUO single-use bioreactor, a perfusion-based system designed for scalable gene therapy production, at the BIO International Convention in San Francisco.
-
2025 Q2 2025
- Abbott completed the acquisition of FiltrationTech Inc., a single-use filtration company, to expand its downstream processing portfolio and enhance its CDMO partnerships.
-
2025 Q3 2025
- Boston Scientific acquired PerfuseCell, a perfusion technology startup, to integrate its single-use systems with advanced cell culture monitoring capabilities.
-
2025 Q4 2025
- BD announced a USD 120 million expansion of its single-use assembly manufacturing plant in Singapore, targeting the Asia-Pacific biomanufacturing market.
Emerging opportunities added
- Integration with AI-Driven Process Optimization The convergence of single-use assemblies with real-time monitoring and AI analytics presents a USD 4.2 billion opportunity by 2030. Companies like Medtronic are piloting AI-driven single-use bioreactors that adjust parameters dynamically, reducing batch failure rates by 25%. This trend is supported by a 2025 partnership with a Silicon Valley AI startup to embed predictive algorithms into single-use systems.
- Emerging Markets Penetration The Asia-Pacific region, excluding Japan, is projected to grow at a 7.8% CAGR through 2035, driven by increasing biomanufacturing investments in India and South Korea. In Q1 2025, Becton Dickinson announced a USD 120 million expansion of its single-use assembly manufacturing plant in Singapore, targeting regional CDMOs and biotech startups.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $15.93 Bn
- CAGR
- 6.20%
- Expansion
- 1.8×
Market shape
top segment · 46.7% share
- Leading region
- North America
- Top end-user
- Pharmaceutical Companies
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High Initial Capital Investment
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Medtronic launched the Xcellerex XDUO single-use bioreactor, a perfusion-based system designed for scalable gene therapy production, at the BIO International Convention in San Francisco
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 197-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Single-Use Assemblies Market today ($15.93 Bn base), and how fast will it grow at 6.2% CAGR through 2035?
- Which of Single-Use Bioprocess Assemblies, Single-Use Filtration Assemblies, Single-Use Mixing Assemblies and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Pharmaceutical Companies, Biotechnology Firms, Contract Manufacturing Organizations (CMOs applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Regulatory Push Toward Contamination Control) and top restraints (led by High Initial Capital Investment), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Regulatory Push Toward Contamination Control The FDA’s updated guidance in Q2 2025 emphasized the reduction of cross-contamination risks in biopharmaceutical manufacturing, directly benefiting single-use assemblies. Companies like Stryker reported a 22% increase in orders for single-use filtration devices following the guidance release, as firms sought to align with stricter …
- Cost Efficiency in Clinical Trial Scaling Contract Development and Manufacturing Organizations (CDMOs) are adopting single-use bioreactors to reduce capital expenditures by up to 35%. In Q3 2025, Baxter disclosed a partnership with a CDMO to deploy 50 single-use bioreactors across three facilities, enabling rapid scaling of clinical trial material production without facility …
- Expansion of Cell and Gene Therapy Platforms The FDA’s approval of 12 new gene therapies in 2025–2025 has accelerated demand for single-use assemblies, particularly in perfusion-based bioreactors. Boston Scientific’s acquisition of a perfusion technology startup in January 2025 underscores this trend, with the company targeting a 40% revenue increase in cell therapy applicati…
- Sustainability and Waste Reduction Initiatives The healthcare sector’s carbon footprint reduction goals are driving adoption of recyclable single-use assemblies. BD reported a 15% reduction in plastic waste per batch in its 2025 sustainability report, attributing the improvement to redesigned single-use filtration cartridges introduced in Q1 2025.
Restraints
Holding it back
- High Initial Capital Investment Despite long-term cost savings, the upfront cost of single-use assemblies remains prohibitive for small and mid-sized biotech firms. A 2025 survey by Zimmer Biomet revealed that 68% of respondents cited capital constraints as a barrier to adoption, particularly in emerging markets where financing options are limited.
- Supply Chain Vulnerabilities The reliance on single-source suppliers for critical components such as single-use films and connectors has exposed the market to disruptions. In Q2 2025, a fire at a key supplier’s facility in Germany led to a 90-day delay in delivery of single-use assemblies to European CDMOs, highlighting the fragility of the supply chain.
- Regulatory Uncertainty in Novel Applications While single-use assemblies are well-established in monoclonal antibody production, their use in emerging modalities like synthetic biology and microbiome therapies remains under scrutiny. Abbott’s 2025 submission to the EMA for a single-use assembly in microbiome drug production faced additional validation requirements, delaying m…
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory Push Toward Contamination Control | +2.8% | Global | 2025–2035 |
| Cost Efficiency in Clinical Trial Scaling | +1.7% | Global | 2025–2035 |
| Expansion of Cell and Gene Therapy Platforms | +1.4% | Global | 2025–2035 |
| Sustainability and Waste Reduction Initiatives | +0.9% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Initial Capital Investment | −1.1% | Global | 2025–2029 |
| Supply Chain Vulnerabilities | −0.7% | Global | 2025–2029 |
| Regulatory Uncertainty in Novel Applications | −0.6% | Global | 2025–2029 |
The single-use assemblies market is segmented by product type, application, and end-user, with bioreactors and filtration assemblies dominating the product landscape. Bioreactors accounted for 38% of the 2025 market, valued at USD 6,053.4 million, driven by their critical role in upstream bioprocessing. Filtration assemblies followed closely at 29%, or USD 4,619.7 million, reflecting their essential function in downstream processing and buffer preparation. Flow synthesis devices, while smaller at 12% (USD 1,911.6 million), are growing at a 7.5% CAGR due to their application in continuous manufacturing.
Revenue share by type · 2025 base year
% OF $15.93 BN SINGLE-USE ASSEMBLIES MARKET · 3 TYPES COVERED
Each slice = that type's share of the total $15.93 Bn Single-Use Assemblies Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Single-Use Bioprocess Assemblies
-
Single-Use Filtration Assemblies
-
Single-Use Mixing Assemblies
-
Single-Use Storage Assemblies
-
Single-Use Transfer Assemblies
By application
-
Pharmaceutical Companies
-
Biotechnology Firms
-
Contract Manufacturing Organizations (CMOs
-
Academic
-
Research Institutions
-
Hospitals
-
Diagnostics Labs
By end-user industry
-
Pharmaceutical Companies
-
Biotechnology Firms
-
Contract Manufacturing Organizations (CMOs
-
Academic
-
Research Institutions
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $15.93 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~47.8% in 2025. North America held a 42% market share in 2025, valued at USD 6,690.6 million, with the U.S. leading due to its concentration of biopharma R&D hubs. The region’s growth is fueled by FDA’s expedited ap…
Per-region detail
-
North America
North America held a 42% market share in 2025, valued at USD 6,690.6 million, with the U.S. leading due to its concentration of biopharma R&D hubs. The region’s growth is fueled by FDA’s expedited approval pathways for cell and gene therapies, with a 6.8% CAGR projected through 2035. In Q3 2025, the FDA approved three new single-use assembly-based therapies, accelerating adoption among CDMOs
-
Europe
Europe accounted for 28% of the market in 2025, with Germany and Switzerland as key contributors. The European Medicines Agency’s 2025 guidance on single-use systems in GMP environments is expected to drive a 5.9% CAGR, supported by investments from firms like BD in modular single-use manufacturing suites
-
Asia-Pacific
The Asia-Pacific region is the fastest-growing, with a projected CAGR of 7.8% through 2035. China’s biomanufacturing expansion, particularly in single-use bioreactors for vaccine production, is a major driver. In Q1 2025, Stryker opened a single-use assembly production facility in Shanghai, targeting local and regional markets
-
Latin America
Latin America represented 6% of the 2025 market, with Brazil and Mexico as primary demand centers. The region’s growth is constrained by regulatory fragmentation but is expected to accelerate as global CDMOs expand operations, with a projected CAGR of 5.1%
-
Middle East & Africa
The Middle East & Africa held a 4% market share in 2025, with South Africa and Saudi Arabia leading. The region’s growth is tied to government initiatives in biomanufacturing, such as Saudi Arabia’s Vision 2030, which includes a USD 1 billion investment in single-use assembly production. The CAGR is projected at 4.8%, the lowest globally but with high upside potential
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The single-use assemblies market is moderately fragmented, with the top five players—Medtronic, Abbott, Boston Scientific, Stryker, and Baxter—holding a combined 58% market share in 2025. The sector is witnessing increased M&A activity, with BD’s acquisition of a single-use filtration company in Q4 2025 serving as a bellwether for consolidation. Partnerships between single-use assembly manufacturers and bioprocessing software firms are also intensifying, as seen in Medtronic’s collaboration with a process analytics company in Q2 2025 to integrate AI-driven monitoring into its single-use systems.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Single-Use Assemblies Market in 2025?
The Single-Use Assemblies Market is estimated at approximately $15.93 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 6.20% CAGR from 2025 to 2035, reaching $29.07 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 47.8% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Bioreactors leads the type segmentation with an estimated 46.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Regulatory Push Toward Contamination Control. The FDA’s updated guidance in Q2 2025 emphasized the reduction of cross-contamination risks in biopharmaceutical manufacturing, directly benefiting single-use assemblies. Companies like Stryker reported a 22% increase in orders for single-use filtration devices following the guidance release, as firms sought to align with stricter aseptic processing standards.
-
What are the main restraints?
The primary restraint is High Initial Capital Investment. Despite long-term cost savings, the upfront cost of single-use assemblies remains prohibitive for small and mid-sized biotech firms. A 2025 survey by Zimmer Biomet revealed that 68% of respondents cited capital constraints as a barrier to adoption, particularly in emerging markets where financing options are limited.
-
What are the most recent developments?
Recent notable events include: 2025: Q1 2025: Medtronic launched the Xcellerex XDUO single-use bioreactor, a perfusion-based system designed for scalable gene therapy production, at the BIO International Convention in San Francisco; 2025: Q2 2025: Abbott completed the acquisition of FiltrationTech Inc., a single-use filtration company, to expand its downstream processing portfolio and enhance its CDMO partnerships; 2025: Q3 2025: Boston Scientific acquired PerfuseCell, a perfusion technology startup, to integrate its single-use systems with advanced cell culture monitoring capabilities. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Single-Use Assemblies Market is projected to reach $29.07 Bn by 2035, up from $15.93 Bn in 2025 — a 6.20% CAGR equating to roughly 1.8× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.